Market Closed - Swiss Exchange 11:30:22 2024-02-21 am EST 5-day change 1st Jan Change
129.6 CHF -0.31% Intraday chart for Medacta Group SA -2.41% +3.18%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Medacta Enters Collaboration for RFID Technology in Healthcare Business MT
Transcript : Medacta Group SA, 2023 Sales/ Trading Statement Call, Feb 02, 2024
Medacta Group Books 17% Jump in FY23 Revenue MT
Medacta to Expand Swiss Facilities to Boost Production Capacity MT
Medacta Group to Launch Optimized Knee Implant MT
Medacta's New Study Shows Accuracy of NextAR Shoulder Application MT
Transcript : Medacta Group SA, Q2 2023 Earnings Call, Sep 22, 2023
Medacta Group Reports Higher H1 Attributable Profit, Revenue MT
Medacta Group SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Transcript : Medacta Group SA, H1 2023 Sales/ Trading Statement Call, Jul 28, 2023
Medacta Posts 21% Increase in H1 Revenue; Raises FY23 Guidance MT
Medacta Group SA Announces Unaudited Revenue Results for the First Half Ended June 30, 2023 CI
Medacta Group SA Updates Revenue Guidance for the Year 2023 CI
Global markets live: Enel, ASML, Adobe, Nikola... Our Logo
Medacta Group Completes First MyPAO Surgery in Europe MT
Exclusive-EQT sounds out banks to manage LimaCorporate IPO - sources RE
Medacta Group SA Approves Distribution for the Year 2022 CI
Medacta's MySpine Platform Shows Accuracy for Pedicle Screw Placement in Clinical Study MT
Medacta Group SA Provides Earnings Guidance for the Year 2023 CI
Medacta Group SA Proposes Dividend CI
Transcript : Medacta Group SA, 2022 Earnings Call, Mar 17, 2023
Medacta Posts Lower FY22 Attributable Profit MT
Medacta Group SA Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Medacta Group SA Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Octavian Lifts Price Target on Medacta Group, Maintains Buy Recommendation MT
Chart Medacta Group SA
More charts
Medacta International SA is a Swiss-based company specialized in medical devices. The Company develops, manufactures and distributes orthopaedic and neurosurgical medical devices. The Company designs a number of products, such as hip products, including hip replacement, hip anatomy, hip diseases, and other products for the preparation of hip surgery; knee product, which encompasses knee anatomy, knee diseases, knee replacement, the stability of the knee and for the preparation of knee surgery; shoulder product, which includes shoulder anatomy, shoulder disease, shoulder replacement, and for the preparation of shoulder operation, and spine product, which includes products for spinal treatments, spinal anatomy and for surgery, among others. Additionally, the Company also offers training and support to healthcare professionals.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
136.5 EUR
Average target price
148.2 EUR
Spread / Average Target
+8.53%
Consensus

Quarterly revenue - Rate of surprise

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer